Pharmacological Mechanisms of Evodiamine in Cancer Therapeutics

Evodiamine, a major indole alkaloid derived from Evodia rutaecarpa fruit, exhibits anticancer activity through multi-target engagement. It inhibits tumour cell proliferation by inducing G2/M cell-cycle arrest and triggers intrinsic apoptosis via mitochondrial depolarisation, cytochrome c release and activation of the caspase cascade. Evodiamine suppresses key survival pathways by inhibiting IκB kinase, thereby preventing NF-κB activation and downregulating antiapoptotic and metastatic gene expression. Concurrently, it activates mitogen-activated protein kinases, notably JNK, to reinforce apoptotic signals and cell-cycle checkpoints. Structural modifications at specific positions on the evodiamine scaffold have been shown to enhance binding affinity and pro-apoptotic potency. Beyond direct cytotoxic effects, evodiamine remodels the tumour microenvironment by downregulating immune checkpoints such as PD-L1 via MUC1-C suppression and synergises with chemotherapeutic agents to overcome resistance without compromising efflux transporter function. Collectively, these pharmacological profiles underscore evodiamine’s promise as a multi-target small molecule in cancer therapeutics, with potential applications spanning monotherapy, chemosensitisation and combination with immuno-therapeutic regimens.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Pharmacological Mechanisms of Evodiamine in Cancer Therapeutics publication trend

The graph below shows the total number of articles in pharmacological mechanisms of evodiamine in cancer therapeutics across all publications each year (not limited to Nature Index journals).

Technical terms

Apoptosis: programmed cell death characterised by caspase activation and DNA fragmentation.

Cell cycle arrest: halting of cell division at defined checkpoints, notably G2/M, to prevent proliferation.

NF-κB: transcription factor that regulates genes involved in cell survival, inflammation and metastasis.

JNK (c-Jun N-terminal kinase): stress-activated kinase that promotes apoptosis and enforces cell-cycle checkpoints.

PD-L1 (Programmed Death Ligand 1): immune checkpoint protein that binds PD-1 on T cells to inhibit their activation.

Mitochondrial membrane potential: electrochemical gradient across the mitochondrial membrane essential for ATP synthesis and a trigger for intrinsic apoptosis when dissipated.

References

1. Pharmacological Actions of Multi-Target-Directed Evodiamine. Molecules (2013).
2. Evodiamine Abolishes Constitutive and Inducible NF-κB Activation by Inhibiting IκBα Kinase Activation, Thereby Suppressing NF-κB-regulated Antiapoptotic and Metastatic Gene Expression, Up-regulating Apoptosis, and Inhibiting Invasion*. Journal of Biological Chemistry (2005).
3. Activation of JNK Contributes to Evodiamine-Induced Apoptosis and G2/M Arrest in Human Colorectal Carcinoma Cells: A Structure-Activity Study of Evodiamine. PLOS ONE (2014).
4. Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis. Journal of Experimental & Clinical Cancer Research (2020).
5. Evodiamine Synergizes with Doxorubicin in the Treatment of Chemoresistant Human Breast Cancer without Inhibiting P-Glycoprotein. PLOS ONE (2014).